Article
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations.
Journal for immunotherapy of cancer - 1 Jul 2021
Li Fenge, Deng Ligang, Jackson Kyle R, Talukder Amjad H, Katailiha Arjun S, Bradley Sherille D, Zou Qingwei, Chen Caixia, Huo Chong, Chiu Yulun, Stair Matthew, Feng Weihong, Bagaev Aleksander, Kotlov Nikita, Svekolkin Viktor, Ataullakhanov Ravshan, Miheecheva Natalia, Frenkel Felix, Wang Yaling, Zhang Minying, Hawke David, Han Ling, Zhou Shuo, Zhang Yan, Wang Zhenglu, Decker William K, Sonnemann Heather M, Roszik Jason, Forget Marie-Andree, Davies Michael A, Bernatchez Chantale, Yee Cassian, Bassett Roland, Hwu Patrick, Du Xueming, Lizee Gregory
Abstract excerpt
BACKGROUND: Neoantigen (NeoAg) peptides displayed at the tumor cell surface by human leukocyte antigen molecules show exquisite tumor specificity and can elicit T cell mediated tumor rejection. However, few NeoAgs are predicted to be shared between patients, and none to date have demonstrated therapeutic value in the context of vaccination. METHODS: We report here a phase I trial of personalized NeoAg peptide...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.